Literature DB >> 7846015

Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.

K Satake1, T Takeuchi.   

Abstract

The carbohydrate antigen 19-9 (CA19-9) and radioimmunoassay have been shown to offer new hope for improving the diagnosis of pancreatic cancer, and various tumor markers (including SPan-1, DUPAN-2, and CA50) have been established. While clinical studies of these markers have found satisfactory sensitivities, only a few studies have compared these tumor markers on the same blood samples. We therefore evaluated the clinical efficacy of SPan-1, CA19-9, DUPAN-2, CA50, carcino-embryonic antigen, and Elastase 1 in detecting pancreatic cancer in identical blood samples.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7846015     DOI： 10.1097/00006676-199411000-00008

Source DB:  PubMed          Journal:  Pancreas        ISSN： 0885-3177            Impact factor:   3.327


  14 in total

Review 1.  Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.

Authors:  Si-Biao Su; Shan-Yu Qin; Wen Chen; Wei Luo; Hai-Xing Jiang
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 2.  Molecular diagnosis of pancreas carcinoma.

Authors:  T M Chu
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

Review 3.  Pancreatic cancer: can we screen? How should we stage?

Authors:  A A Parikh; A M Lowy
Journal:  Curr Gastroenterol Rep       Date:  1999-04

4.  Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.

Authors:  Huiyuan Tang; Sudhir Singh; Katie Partyka; Doron Kletter; Peter Hsueh; Jessica Yadav; Elliot Ensink; Marshall Bern; Galen Hostetter; Douglas Hartman; Ying Huang; Randall E Brand; Brian B Haab
Journal:  Mol Cell Proteomics       Date:  2015-03-02       Impact factor: 5.911

Review 5.  Intensity of follow-up after pancreatic cancer resection.

Authors:  Jason A Castellanos; Nipun B Merchant
Journal:  Ann Surg Oncol       Date:  2013-10-04       Impact factor: 5.344

6.  Diagnosis of pancreatic cancer using serum proteomic profiling.

Authors:  Sudeepa Bhattacharyya; Eric R Siegel; Gloria M Petersen; Suresh T Chari; Larry J Suva; Randy S Haun
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

7.  The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour.

Authors:  Niels Teich; Jörg Kleeff; Herbert Lochs; Joachim Mössner; Volker Keim; Helmut Friess; Johann Ockenga
Journal:  BMC Gastroenterol       Date:  2005-06-21       Impact factor: 3.067

8.  Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens.

Authors:  Brian B Haab; Ying Huang; Seetharaman Balasenthil; Katie Partyka; Huiyuan Tang; Michelle Anderson; Peter Allen; Aaron Sasson; Herbert Zeh; Karen Kaul; Doron Kletter; Shaokui Ge; Marshall Bern; Richard Kwon; Ivan Blasutig; Sudhir Srivastava; Marsha L Frazier; Subrata Sen; Michael A Hollingsworth; Jo Ann Rinaudo; Ann M Killary; Randall E Brand
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

9.  Serum tumor markers in pancreatic cancer-recent discoveries.

Authors:  Felix Rückert; Christian Pilarsky; Robert Grützmann
Journal:  Cancers (Basel)       Date:  2010-06-02       Impact factor: 6.639

10.  Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA.

Authors:  F Maire; S Micard; P Hammel; H Voitot; P Lévy; P-H Cugnenc; P Ruszniewski; P Laurent Puig
Journal:  Br J Cancer       Date:  2002-08-27       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.